In 2023, the FDA deemed 19 peptides too unsafe to be dispensed by compounding pharmacies. Now, under RFK Jr., the agency is poised to reverse itself despite the fact that few BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved FDA to weigh easing limits on unproven peptides favored by RFK Jr. and other MAHA figures Pittsburgh Post Gazette Orthopedic Use of BPC 157 Sports Med Review